NewsRx

Search our medical news database

Conference Coverage (ASCO)

Canarypox Vector Explored as Immunotherapy Vehicle

Published in Cancer Weekly, June 1st, 1998

A canarypox vector, ALVAC, is safe and was well tolerated after intratumoral injection, reported a multinational research team.

Dannielle Lienard represented colleagues from Pasteur Merieux Connaught, France, the University Hospital of Zurich, Switzerland, the Institut Curie, France, and the University Hospital Lausanne, Switzerland, and presented phase I clinical trial data at the 34th Annual Meeting of the American Society of Clinical Oncology, held May 16-19, 1998, in Los Angeles, California (abstract "Intratumoral Administration of Canarypox Virus Expressing Human IL-2 [Interleukin-2] Gene (ALVAC-IL-2) in Cancer Patients: Results of a Phase I Study").

...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook